WallStSmart

Evaxion Biotech AS (EVAX)vsInsmed Inc (INSM)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Insmed Inc generates 7956% more annual revenue ($606.42M vs $7.53M). EVAX leads profitability with a -102.4% profit margin vs -210.5%. INSM earns a higher WallStSmart Score of 39/100 (F).

EVAX

Avoid

21

out of 100

Grade: F

Growth: 3.7Profit: 2.0Value: 5.0Quality: 4.5
Piotroski: 5/9Altman Z: -14.71

INSM

Hold

39

out of 100

Grade: F

Growth: 8.0Profit: 2.0Value: 6.7Quality: 6.3
Piotroski: 6/9Altman Z: -3.77

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

EVAX1 strengths · Avg: 8.0/10
Price/BookValuation
2.0x8/10

Reasonable price relative to book value

INSM1 strengths · Avg: 10.0/10
Revenue GrowthGrowth
152.6%10/10

Revenue surging 152.6% year-over-year

Areas to Watch

EVAX4 concerns · Avg: 2.8/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$31.53M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-100.2%2/10

ROE of -100.2% — below average capital efficiency

Revenue GrowthGrowth
-100.0%2/10

Revenue declined 100.0%

INSM4 concerns · Avg: 2.5/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Price/BookValuation
39.4x2/10

Trading at 39.4x book value

Return on EquityProfitability
-249.3%2/10

ROE of -249.3% — below average capital efficiency

Free Cash FlowQuality
$-294.19M2/10

Negative free cash flow — burning cash

Comparative Analysis Report

WallStSmart Research

Bull Case : EVAX

The strongest argument for EVAX centers on Price/Book.

Bull Case : INSM

The strongest argument for INSM centers on Revenue Growth. Revenue growth of 152.6% demonstrates continued momentum. PEG of 1.09 suggests the stock is reasonably priced for its growth.

Bear Case : EVAX

The primary concerns for EVAX are EPS Growth, Market Cap, Return on Equity.

Bear Case : INSM

The primary concerns for INSM are EPS Growth, Price/Book, Return on Equity.

Key Dynamics to Monitor

EVAX profiles as a turnaround stock while INSM is a hypergrowth play — different risk/reward profiles.

INSM carries more volatility with a beta of 1.17 — expect wider price swings.

INSM is growing revenue faster at 152.6% — sustainability is the question.

EVAX generates stronger free cash flow (-7M), providing more financial flexibility.

Bottom Line

INSM scores higher overall (39/100 vs 21/100) and 152.6% revenue growth. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Evaxion Biotech AS

HEALTHCARE · BIOTECHNOLOGY · USA

Evaxion Biotech A / S, a clinical-stage artificial intelligence and immunology platform company, identifies and develops novel immunotherapies for the treatment of various cancers, bacterial diseases, and viral infections. The company is headquartered in Hoersholm, Denmark.

Insmed Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Insmed Incorporated, a biopharmaceutical company, develops and markets therapies for patients with rare and serious diseases. The company is headquartered in Bridgewater, New Jersey.

Want to dig deeper into these stocks?